Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof

2:

• An isolated nucleic acid sequence encoding a complementarity determining region of claim 1.

3:

• As isolated variable region selected from the group consisting of:
• an isolated light chain variable region comprising the light chain complementarity determining regions of SEQ ID NOS:7, 8 and/or 9, or a variant thereof and an isolated heavy chain variable region comprising the heavy chain complementarity determining regions of SEQ ID NOS:10, 11 and/or 12, or a variant thereof.

4:

• The variable region according to claim 3 wherein the isolated light chain variable region comprises the amino acid sequence of SEQ ID NO:16, or a variant thereof.

5:

• The variable region according to claim 3 wherein the isolated heavy chain variable region comprises the amino acid sequence of SEQ ID NO:14, or a variant thereof.

6:

• An isolated nucleic acid sequence encoding the variable region of claim 3.

7:

• The nucleic acid sequence of claim 6 comprising the light chain variable region of SEQ ID NO:15, or a variant thereof.

8:

• The nucleic acid sequence of claim 6 comprising the heavy chain variable region of SEQ ID NO:13, or a variant thereof.

9:

• A binding protein comprising one or more variable regions of claim 3.

10:

• The binding protein according to claim 9 comprising the light chain complementarity determining regions comprising the amino acid sequences defined by SEQ ID NOS:
• 7, 8 and/or 9 and the heavy chain complementarity determining regions comprising the amino acid sequence defined by SEQ ID NOS:
• 10, 11 and/or 12, or a variant thereof.

11:

• The binding protein of claim 9 comprising the light chain variable region of SEQ ID NO:16, or a variant thereof.

12:

• The binding protein of claim 9 comprising the heavy chain variable region of SEQ ID NO:14, or a variant thereof.

13:

• The binding protein of claim 9 comprising the light chain variable region of SEQ ID NO:16 and the heavy chain variable region of SEQ ID NO:14, or a variant thereof.

14:

• The binding protein of claim 9, wherein the binding protein binds to prostate stem cell antigen (SEQ ID NO:17), variant HnRNPG, variant HnRNPG having the amino acid sequence of SEQ ID NO:71, variant HnRNPG having the amino acid sequence of SEQ ID NO:113 with one or more amino acid substitutions at positions 216, 218, 219 and/or 222, or a polypeptide comprising the amino acid sequence of SEQ ID NO:23, SEQ ID NO:41, SEQ ID NO:
• 111, or SEQ ID NO:112.

15:

• The binding protein of claim 14, wherein the binding protein is specific for a polypeptide comprising the amino acid sequence of SEQ ID NO:23, SEQ ID NO:41, SEQ ID NO:111 or SEQ ID NO:112.

17:

• The binding protein of claim 9, wherein the binding protein is an antibody.

18:

• The binding protein of claim 17, wherein the antibody is an antibody fragment.

19:

• The binding protein of claim 18, wherein the antibody fragment is a Fab, Fab′, F(ab′)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, or multimers thereof or bispecific antibody fragments.

20:

• An isolated nucleic acid sequence encoding the binding protein according to claim 9.

21:

• A composition comprising the binding protein according to claim 9 and a pharmaceutically acceptable excipient, carrier, buffer or stabilizer.

22:

• An immunoconjugate comprising (1) a binding protein according to claim 9 that binds to an antigen on a cancer cell attached to (2) a cancer therapeutic.

23:

• The immunoconjugate of claim 22, wherein the cancer therapeutic is a cytotoxin.

24:

• The immunoconjugate of claim 23, wherein the cytotoxin is a ribosome-inactivating polypeptide.

25:

• The immunoconjugate according to claim 23, wherein the cytotoxin is selected from the group consisting of gelonin, bouganin, saporin, ricin, ricin A chain, bryodin, diphtheria, restrictocin and Pseudomonas exotoxin A or variants thereof.

26:

• The immunoconjugate of claim 23, wherein the cytotoxin is modified bouganin or a variant thereof.

27:

• The immunoconjugate of claim 23, wherein the cytotoxin is a truncated form of Pseudomonas exotoxin A that consists of amino acids 252-608 or a variant thereof.

28:

• The immunoconjugate according to claim 22 wherein the immunotoxin is internalized by the cancer cell.

29:

• The immunoconjugate according to claim 22, comprising the amino acid sequence of SEQ ID NO:49.

30:

• The immunoconjugate according to claim 21, comprising the amino acid sequence of SEQ ID NO:51.

31:

• An isolated nucleic acid sequence encoding the immunoconjugate according to claim 22.

32:

• The isolated nucleic acid sequence according to claim 31, comprising the nucleic acid sequence of SEQ ID NO:48.

33:

• The isolated nucleic acid sequence according to claim 31, comprising the nucleic acid sequence of SEQ ID NO:50.

34:

• A composition comprising the immunoconjugate according to claim 22 with a pharmaceutically acceptable excipient, carrier, buffer or stabilizer.

35:

• A use of an effective amount of the immunoconjugate according to claim 22 for treating or preventing cancer.

36:

• The use according to claim 35 additionally comprising the use of one or more further cancer therapeutic agent for the manufacture of a medicament for simultaneous, separate or sequential treatment or prevention of cancer.

37:

• A kit for treating or preventing cancer comprising an effective amount of the immunoconjugate of claim 22, and directions for the use thereof to treat or prevent the cancer.

39:

• A kit for diagnosing cancer comprising the binding proteins of claim 9 that binds to an antigen on or in the cancer cell and instructions for the use thereof.

40:

• A diagnostic agent comprising (1) a binding protein according to claim 9 that binds to an antigen on or in a cancer cell attached to (2) a label that produces a detectable signal, directly or indirectly.

41:

• The diagnostic agent of claim 40, wherein the label is a radioisotype, a fluorescent compound, a chemiluminescent compound, an enzyme, an imaging agent or a metal ion.

42:

• A kit comprising the diagnostic agent of claim 40 and instructions for the use thereof.

43:

• A recombinant expression vector comprising the nucleic acid molecule of claim 2.

44:

• A host cell comprising the recombinant expression vector of claim 43.

45:

• An isolated polypeptide, comprising the amino acid sequence of SEQ ID NO:23, SEQ ID NO:41, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113 with one or more amino acid substitutions at positions 216, 218, 219 and/or 222, or SEQ ID NO:71, or a variant thereof.

46:

• An isolated polypeptide, consisting of the amino acid sequence of SEQ ID NO:23, SEQ ID NO:41, SEQ ID NO:111, SEQ ID NO:112 SEQ ID NO:113 with one or more amino acid substitutions at positions 216, 218, 219 and/or 222, or SEQ ID NO:71, or a variant thereof.

47:

• An isolated nucleic acid sequence encoding the isolated polypeptide of claim 45.

48:

• A recombinant expression vector comprising the nucleic acid sequence of claim 47.

49:

• A method of detecting or monitoring cancer in a subject having or suspected of having cancer, comprising detecting the isolated polypeptide according to claim 45 on or in a cell in the sample, wherein cancer is indicated, if the isolated polypeptide is detected on or in the cell.

50:

• A pharmaceutical composition comprising an effective amount of the isolated polypeptide according to claim 45 or fragment thereof in admixture with a suitable diluent or carrier.

51:

• The pharmaceutical composition of claim 50, further comprising an adjuvant.

52:

• (canceled)